This is default featured slide 1 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 2 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 3 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 4 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 5 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

Carlyle acquires Knack RCM and Equalize RCM to create an AI-native, global multi-specialty healthcare RCM platform

Global investment firm Carlyle has acquired a majority stake in US healthcare revenue cycle management providers Knack RCM and EqualizeRCM. This move aims to create a global, AI-native, multi-specialty RCM platform. The combined entity will leverage AI and global delivery to enhance operational scale and client outcomes, addressing critical financial risks for healthcare providers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iHPezoQ
via IFTTT

Two separate venues for pharma industry expos in Delhi-NCR

CPHI India and PMEC India are expanding their pharmaceutical expos to two venues in Delhi-NCR. This move aims to support the rapid growth of India's pharma sector. The events will offer greater business engagement and specialized networking. CPHI India will focus on ingredients and formulations. PMEC India will showcase machinery and manufacturing technologies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Uh081QY
via IFTTT

Bombay HC backs GSK in Paxil trademark row against Shreya Life Sciences

The Indian subsidiary of the UK-based GSK PLC had urged the court to cancel the mark used by the local company in pharmaceutical and medicinal preparations. It argued that despite getting the mark more than two decades ago, Shreya Life Sciences had never used it and hence, under Section 47 of the Trade Marks Act, the registration was liable to be removed from the register of trade marks on account of non-use.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9tGdrAP
via IFTTT

Aurobindo Pharma arm CuraTeQ gets Health Canada nod for biosimilar

Aurobindo Pharma announced a significant development today. Its subsidiary, CuraTeQ Biologics, has received a compliance notice from Health Canada for its cancer drug Bevqolva. This approval marks a crucial step for the bevacizumab biosimilar. Bevqolva is used to treat various cancers. Health Canada's nod confirms its safety and efficacy. This opens new avenues for cancer treatment in Canada.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4Zb1YWw
via IFTTT

Drugs at your door: Signs of a disruption taking shape in India

India Pharmacy Retail Quick Commerce: India's medicine delivery is seeing a change. Quick-commerce apps are making it easier to buy medicines regularly. While total sales are not growing much, people are buying more wellness products. Acute care medicines are seeing fewer sales. This shift is happening as more people shop online for health items. The market is changing, not booming yet.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WA1ktfa
via IFTTT

ORS sales melt in March after govt's stricter labelling norms

India’s oral rehydration solution (ORS) market has declined after regulatory action restricted the labelling of sugary drinks as ORS, affecting pharmaceutical companies that depend on seasonal demand.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1hk20ED
via IFTTT

RPG Life Sciences bets big on API business, eyes GLP-1 entry by August-September

RPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company also aims to enter the GLP-1 weight-loss therapy market by August-September. Despite geopolitical risks, RPG Life Sciences is strategically focusing on niche, complex molecules and expanding into new therapy areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0UcztMm
via IFTTT